A therapy session can finish twice. First, when the conversation ends. Then, when the clinician has translated that conversation into the language of the record: symptoms, interventions, progress, next steps. The second ending attracts less attention. It is also where Eleos Health has found a business.
The company's proposition is easy to understand if you have ever completed a form after doing something difficult. Remembering the work and proving the work are separate activities. In community-based care, Eleos tries to bring them closer together, using AI to draft documentation and catch problems while someone can still correct them.
- The buyer: care organizations, including mental health agencies and addiction treatment programs.
- The job: draft notes, check documentation and support clinical and reimbursement workflows.
- The catch: clinicians still review the output. A fluent paragraph does not absolve anyone of responsibility.
The work that follows the work
Eleos began in 2020. Its early announcements named Alon Joffe, Dror Zaide, Alon Rabinovich and clinical researcher Shiri Sadeh-Sharvit as co-founders. Their chosen territory was behavioral health, where the conversation contains much of the treatment and much of the information needed to describe it. A notebook was an awkward bridge between those two purposes.
The documentation product now takes live session audio or a clinician's short summary and proposes structured note content. The provider selects, edits and approves it. Eleos also offers session analytics and reporting for supervisors. This matters because the customer is an organization with many practitioners, templates and obligations, each of which can turn a tidy demo into a messy working day.
Its customers include community behavioral health agencies and substance use disorder programs; the company has also expanded into home health and hospice. These are settings where care moves between people, places and teams. The software has to follow. That apparently modest requirement produced one of Eleos's most revealing product stories.
The desk was the wrong assumption
In Eleos's account of its work with Trilogy, the first mismatch was physical: an office-oriented product did not suit outreach workers. Staff needed to document from a phone. The organizations developed Outreach together, connecting mobile input to the health record.
“If you're not embedded within the user's workflow, it doesn't matter how good the quality of the note is.”
Shon Cohen / Eleos Outreach product manager
Trilogy reported roughly 80% less documentation time. Staff could draft a note, add the encounter's particulars and send it to CareLogic. That made the benefit visible during training. The lesson readers can copy is to test the entire trip from input to signed record, on the device workers actually carry. An impressive draft stranded in the wrong application is another errand.
A note is also a financial document
A clinical note has several readers. The next practitioner wants context. A quality team wants to see whether the record supports the care plan. A payer wants documentation that supports reimbursement. One conversation can therefore produce several kinds of administrative trouble.
Eleos introduced Compliance alongside its January 2025 financing announcement. The product reviews notes for potential documentation problems and helps quality teams concentrate on the records needing attention. Legal and regulatory experts retained by the National Council for Mental Wellbeing helped guide its development. Automated screening of every note is the ambition; a guarantee that every error is detected would be a different claim.
In April 2026, the company expanded its clinical insights, revenue cycle and compliance agents. Eligibility Intelligence flags coverage changes; coding support proposes codes; a clinical co-pilot brings together client information and vetted guidance. The expansion follows a plausible sequence: once software sits beside the note, it can help with the decisions and checks around the note.
This is where Eleos positions itself against the growing market for AI scribes. Blueprint and Upheal also offer therapy documentation tools. Eleos's pitch emphasizes enterprise community care and the chain linking documentation, quality and reimbursement. Buyers should compare those specific workflows. The phrase “AI-powered” has become about as discriminating as “electric.”
Put the percentages back in their setting
The company has more than testimonials. A 2023 randomized trial at Missouri's Ozark Center enrolled 47 adults: 23 received therapy supported by Eleos and 24 received treatment as usual. Over the study period, reported depression symptoms fell 34% in the supported group and 20% in the comparison group; anxiety symptoms fell 29% and 8%, respectively.
Symptom reduction over two months
Attendance also favored the supported group. Satisfaction and perceived helpfulness did not differ between groups. The sample was small, and company-affiliated researchers participated. Those details belong beside the percentages: the findings support further examination, without establishing the same effect in every population or care setting.
Operational scale is a separate measure. In its 2025 retrospective, Eleos reported processing more than 5.2 million notes and returning more than 655,000 hours to healthcare workers. Those are company-reported usage and time-saving figures, not independent clinical outcomes. They nevertheless indicate that the product has moved well beyond the demonstration stage.
The invoice behind the promise
Eleos sells organizational software subscriptions. A public June 2025 agreement with Community Integrated Health Services lists $59,400 annually for documentation for up to 50 users, plus a $20,000 implementation payment. At full allocation, the subscription works out to $99 per user per month. That is one agreement's economics, rather than a universal rate card.
$79,400 in combined first-year listed charges. Different products and contracts may carry different terms.
The agreement also lays out configuration, testing and training. This makes the buying decision more substantial than purchasing access to a chatbot. An organization is paying to fit a tool into its records and routines. Its return depends on adoption, corrections required and what happens to the hours recovered.
Investors have financed that work. A $20 million Series A in 2022 was followed by a $40 million Series B in 2023. The $60 million Series C, led by Greenfield Partners in January 2025, brought the company-reported total above $120 million. Funding buys development and distribution capacity; it does not settle whether an individual clinic should buy the software.
Time saved needs an owner
Eleos's technical direction includes Polaris AI, launched in October 2025 using Google Cloud's Gemini models and Eleos's clinical data. The company describes an audio-native approach capable of interpreting vocal information that a transcript can discard. The practical question remains whether those capabilities produce useful, accurate material for a clinician to review.
Distribution is changing, too. In February 2026, CalMHSA selected Eleos alongside Streamline's SmartCare EHR. The initial arrangement gave 27 California counties the option to use the combined offering. An option is meaningful access; it should not be counted as 27 completed deployments.
For a prospective customer, the constraints are concrete. Someone must own clinical review. Consent and data handling must fit the setting. The right templates must reach the right record. Eleos's security information places responsibility for recording consent with the provider. A clinician's trust in the process is part of implementation, not a decorative extra.
There is also a management choice. Trilogy's leaders described time savings as a way to make difficult jobs less burdensome, rather than an excuse to raise productivity expectations. That is an editorially useful distinction: software can recover a break, or management can immediately book over it. Both count as time saved on a dashboard. Only one feels like relief.
The strongest argument for Eleos is therefore modest and testable. Start with a real encounter. Follow the note into the record. Count the edits, the checks and the minutes. Then ask the person who signs it whether the working day ends any closer to when the session does.